METHODS FOR IDENTIFYING ANTIBODIES WITH REDUCED IMMUNOGENICITY Russian patent published in 2018 - IPC C07K16/24 C12N15/13 C12N5/22 A61K39/395 A61P37/00 

FIELD: chemistry.

SUBSTANCE: present invention relates to a variant of a reference anti-TNF-α antibody or reference binding fragment of the anti-TNF-α antibody, a nucleic acid molecule, a host cell, a pharmaceutical composition, and a method of treatment. Described variant of the reference antibody or its binding fragment contains six complementarity determining regions (CDRs) having amino acid sequences corresponding to SEQ ID NO: 5 (CDR-H1), SEQ ID NO: 6 (CDR-H2), SEQ ID NO: 7 (CDR-H3), SEQ ID NO: 8 (CDR-L1), SEQ ID NO: 9 (CDR-L2) and SEQ ID NO: 10 (CDR-L3), wherein the variant comprises substitute Y2K in CDR-H1 and where six CDRs collectively have up to 8 amino acid substitutions compared to the CDR sequences of the reference antibody or binding fragment.

EFFECT: presented solutions can be used to treat such an immune disorder as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis and axial spondylitis.

10 cl, 22 dwg, 11 ex